MS4A1 and B-cell chronic lymphocytic leukemia: Rituximab, a type I anti-CD20 monoclonal antibody, has transformed treatment for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [105,106].